MarketFriction

Hester Biosciences Ltd

NSE HESTERBIO · BSE 524669 · Pharmaceuticals
₹2,126.80 -2.25%
NSE close2026-10-01
52 week range1,239.30 - 2,683.60
Market cap₹1,848 Cr.
P/E34.8
Price band 20% Delivery 57.9%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales7067798284638284717710077
Expenses575763656558636159606654
Operating Profit13101618195192312183423
OPM %19%15%20%21%23%8%23%27%17%23%34%29%
Other Income625239-63122289
Interest82756-4622253
Depreciation444444444467
Profit before tax7610111213420171425102
Tax %40%37%35%29%29%15%59%14%16%31%34%5%
Net Profit44678112171491797
EPS in Rs4.814.685.827.459.6413.711.5219.3316.9910.3118.78114.00
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales101123136178183214235266305311333326
Expenses678289110128146175215251250246239
Operating Profit344147685569605154628787
OPM %34%33%35%38%30%32%26%19%18%20%26%27%
Other Income103761142015819105
Interest4447774920131112
Depreciation6710121313172117171922
Profit before tax2531365741505440324076157
Tax %23%26%36%28%25%31%26%30%34%27%24%
Net Profit1923234131353928212957137
EPS in Rs22.5727.6830.1248.8734.2940.4746.2231.3022.2132.3165.41160.08
Dividend Payout %18%19%33%23%19%25%22%26%27%22%17%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth13%9%8%4%
Compounded Profit Growth11%8%26%41%
Stock Price CAGR11%-3%9%13%
Return on Equity14%12%11%16%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital999999999999
Reserves7693113132169193220251271283306352
Borrowings5559666990121105228274244213195
Other Liabilities2025253532657874116126126123
Total Liabilities160186213244299387411562670662653678
Fixed Assets6065102110145143133237259240233411
CWIP33362132774109821491711839
Investments00-0-0-0-0-02125303443
Other Assets688589102148170169222237221203215
Total Assets160186213244299387411562670662653678
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity20193538473758924486564
Cash from Investing Activity-21-13-30-26-21-73-42-117-77-22-20-18
Cash from Financing Activity7-72-11319-1811242-26-52-49
Net Cash Flow5-16128-17-23-12-0-7-3
Free Cash Flow1551524-3617-87-54244447
CFO/OP100%74%102%100%92%86%105%43%63%112%123%90%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days729579876711684861099486105
Inventory Days431627376505540834452424399288291323
Days Payable68109841009326120410114198122110
Cash Conversion Cycle434614371491514690332409367284255318
Working Capital Days761129082106104134113881127454
ROCE %15%19%19%20%26%16%18%14%9%9%10%15%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%
FIIs0.42%0.43%0.43%0.52%0.61%0.59%0.87%0.51%0.53%0.52%0.38%0.31%
DIIs0.00%0.00%0.00%0.00%0.00%0.02%0.02%0.02%0.00%0.01%0.00%0.00%
Public45.84%45.83%45.84%45.74%45.66%45.65%45.38%45.73%45.73%45.75%45.88%45.95%
No. of Shareholders13,34213,45012,84411,30511,53811,47311,85311,81012,26012,60312,37311,961

Fundamentals

Market Cap₹ 1,848 Cr.
Current Price₹ 2,165
Stock P/E34.8
Book Value₹ 423
ROCE15.2 %
ROE15.9 %
Dividend Yield0.51 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)41%
Consolidated figures.
Valuation
Market capRs 1,809 Cr
Enterprise valueRs 1,998 Cr
P/E (TTM)13.29x
Price to book5.02x
Price to sales5.55x
EV / EBITDA10.44x
EV / EBIT11.78x
EV / sales6.13x
Price to cash flow28.21x
Earnings yield7.53%
Dividend yield0.52%
P/E, 3-year average40.29x
P/B, 3-year average3.48x
P/E, 5-year average45.64x
P/B, 5-year average4.79x
Profitability
Operating margin (excl. other income)26.12%
Operating margin (incl. other income)31.76%
EBITDA margin58.72%
Pre-tax margin48.31%
Net profit margin41.81%
Net margin, latest quarter125.56%
ROE16.50%
ROCE16.03%
ROA8.36%
ROE, 3-year average10.73%
ROCE, 3-year average11.78%
ROA, 3-year average5.12%
ROE, 5-year average11.63%
ROCE, 5-year average11.77%
ROA, 5-year average5.56%
ROIC (approx.)23.43%
Tax rate24.20%
Other income / net worth5.21%
Growth
Sales growth (latest year)6.91%
Profit growth (latest year)102.40%
Sales CAGR, 3 years7.72%
Sales CAGR, 5 years9.19%
Profit CAGR, 3 years27.84%
Profit CAGR, 5 years10.08%
Sales growth QoQ-22.84%
Profit growth QoQ506.88%
Sales growth YoY (latest quarter)-8.17%
Profit growth YoY (latest quarter)489.90%
Per share
EPS (TTM)Rs 160.08
EPS (latest year)Rs 65.41
EPS (latest quarter)Rs 114.00
EPS, 3-year averageRs 39.98
EPS, 5-year averageRs 39.49
Book value per shareRs 423.47
Sales per shareRs 382.91
Cash flow per shareRs 75.40
Free cash flow per shareRs 55.25
Dividend per share (latest year)Rs 11.00
Dividend per share, 3-year averageRs 8.01
Dividend per share, 5-year averageRs 8.40
Dividends
Dividend payout16.82%
Dividend payout, 3-year average21.85%
Dividend payout, 5-year average22.55%
Efficiency
Asset turnover0.49x
Fixed asset turnover0.81x
Inventory turnover1.54x
Inventory days237 days
Debtor days105 days
Debtors turnover3.49x
Creditor days110 days
Cash conversion cycle318 days
Working capital days54 days
Leverage
Total debtRs 195 Cr
Cash and bankRs 7 Cr
Net debtRs 188 Cr
Debt to equity0.54x
Net debt / EBITDA0.98x
Interest coverage13.89x
Current ratio (filing 2026-03-31)1.37x
Quick ratio (filing 2026-03-31)0.89x
Trade payables (filing 2026-03-31)Rs 25 Cr
Owners' fund to total sources53.14%
Debt to assets28.73%
Cash flow
Cash from Operating Activity (latest year)Rs 64 Cr
Cash from Investing Activity (latest year)Rs -18 Cr
Cash from Financing Activity (latest year)Rs -49 Cr
Net Cash Flow (latest year)Rs -3 Cr
Free cash flow (latest year)Rs 47 Cr
FCFE (approx.: FCF + change in debt)Rs 29 Cr
Cash from ops / profit, 5 years1.21x
Sales to cash flow5.19x
Statement figures
Net sales (TTM)Rs 326 Cr
Net sales (latest year)Rs 333 Cr
Sales (latest quarter)Rs 77 Cr
Operating profit excl. other income (latest year)Rs 87 Cr
Operating profit (latest quarter)Rs 23 Cr
Other income (TTM)Rs 105 Cr
EBITDA (TTM)Rs 191 Cr
PBDT (TTM)Rs 179 Cr
Profit before tax (TTM)Rs 157 Cr
Tax (latest year)Rs 18 Cr
Net profit (TTM)Rs 136 Cr
Net profit (latest year)Rs 56 Cr
Net profit (latest quarter)Rs 97 Cr
Depreciation (TTM)Rs 22 Cr
Depreciation (latest quarter)Rs 7 Cr
Interest (TTM)Rs 12 Cr
Cost of goods sold (latest year)Rs 112 Cr
Total expenditure (latest year)Rs 246 Cr
Total income (latest year)Rs 351 Cr
Share capitalRs 9 Cr
ReservesRs 352 Cr
Shareholders' fundsRs 360 Cr
Total assetsRs 678 Cr
Net blockRs 411 Cr
Capital work in progressRs 9 Cr
InvestmentsRs 43 Cr
ReceivablesRs 95 Cr
InventoryRs 73 Cr
Other liabilitiesRs 123 Cr
Shares outstanding (crore)0.85
Ownership
Promoter holding53.73% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 13.3 is the lowest in its own 9.4-year history (median 44.5, low 13.3, high 140.3).
P/B 5.02 is at the 15th percentile (median 6.95).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodHESTERBIONifty 50Difference
1 week-3.4%-2.8% -0.6 pts
1 month-3.3%-6.8% +3.4 pts
3 months-3.3%-7.6% +4.4 pts
6 months+68.9%+0.4% +68.5 pts
1 year+8.9%-9.9% +18.8 pts
2 years-13.4%-13.6% +0.2 pts
3 years+27.8%+14.2% +13.7 pts
5 years-13.5%+27.9% -41.4 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.05%0 +1%

Red flags

F-score 8 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹77 Cr -8.3% vs Jun 2025. Net profit ₹97 Cr +470.6%.
Against our estimate for Jun 2026: sales -24.9%, profit +415.2% big beat. Our estimate for Sep 2026: sales Rs 76 Cr, profit Rs 14 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-14Dividend - Rs 11 Per Share
2025-08-06Dividend - Rs 7 Per Share
2024-08-22Dividend - Rs 6 Per Share
2024-08-22Annual General Meeting
2023-09-13Annual General Meeting/Dividend - Rs 8 Per Share
2022-08-11Annual General Meeting/Dividend - Rs 10 Per Share
2021-08-05 Dividend - Rs 10 Per Share
2020-08-27 Dividend - Rs 6.60 Per Share
2019-07-18 Dividend - Rs 7 Per Share
2018-11-09 Interim Dividend - Rs 2 Per Sh
2018-08-30 Interim Dividend Rs 2 Per Share
2018-08-02 Dividend- Rs 6 Per Share
2017-11-16 Interim Dividend - Rs 4/- Per Share (Purpose Revised)
2017-07-20 Dividend - Rs 2.30 Per Share
2016-11-03 Interim Dividend Rs 3/- Per Share
2016-07-21 Dividend - Rs 1.10/- Per Share
2016-03-17 Interim Dividend - Rs 3/- Per Share (Purpose Revised)
2015-09-10 Annual General Meeting/ Dividend - Rs 3.10/- Per Share
DateTypeWhat it says
2026-09-04General UpdatesShareholders approval for Reclassification Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter and Promoter Group category to Public category shar...
2026-09-04Shareholder meetingProceedings of Postal Ballot. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report together ...
2026-08-27Credit RatingCredit Rating
2026-08-04Shareholder meetingNotice of Postal Ballot
2026-08-01Concall / analyst meetTranscript
2026-07-31General UpdatesGeneral Updates
2026-07-30Concall / analyst meetLink of Recording
2026-07-30Press ReleaseA press release dated July 30, 2026, titled "20260730 Q1 FY27 Press Release".
2026-07-30Board meeting outcomeHester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-25Concall / analyst meetSchedule of meet
2026-07-25General UpdatesIntimation pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-07-21Shareholder meetingProceedings of Annual General Meeting held on July 21, 2026. Further, the company has informed the Exchange regarding voting results along with copy o...
2026-07-09General UpdatesDisclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sale of Equity Investment in Texas Li...
2026-07-08CorrigendumCorrigendum to Notice of Annual General Meeting to be held on July 21, 2026
2026-06-18Record DateRecord date for the purpose of Dividend & Meeting is 14-Jul-2026.
2026-06-18Shareholder meetingNotice of Annual General Meeting to be held on July 21, 2026
2026-05-20General UpdatesGeneral Updates - Announcement under Regulation 30 of Listing Regulations - Disclosure on amendments in loan agreement of Hester Africa
2026-05-20General UpdatesGeneral Updates
2026-05-18Concall / analyst meetTranscript
2026-05-15General UpdatesGeneral Updates
2026-05-15Concall / analyst meetLink of Recording
2026-05-15General UpdatesGeneral Updates
2026-05-15General UpdatesIntimation of receipt of request for Reclassification from the Promoters to the Public category in accordance with Regulation 31A of SEBI (Listing...
2026-05-15AppointmentAppointment of Ms. Priya Gandhi as Executive Director of the company w.e.f. October 28, 2026.
2026-05-15Press ReleaseA press release dated May 15, 2026, titled "20250515 Press Release Q4 & FY26".
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Hester Biosciences Ltd?

Hester Biosciences Ltd (HESTERBIO) has a market capitalisation of Rs 1,848 Cr. at the 2026-10-01 close.

What is the P/E ratio of Hester Biosciences Ltd?

Hester Biosciences Ltd trades at a P/E of 34.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Hester Biosciences Ltd's latest quarterly results?

In the Jun 2026 quarter, Hester Biosciences Ltd sales was Rs 77 Cr (-8.3% vs Jun 2025) and net profit was Rs 97 Cr.

What is the 52-week high and low of Hester Biosciences Ltd?

The 52-week high is Rs 2,683.60 and the 52-week low is Rs 1,239.30.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03